Congressionally Directed Medical Research Programs -- Prostate Cancer Research Program -- Impact Award

Funding Agency:
Department of Defense

The PCRP Impact Award mechanism was first offered in FY10. Since then, 216 Impact Award applications have been received, and 31 have been recommended for funding. 

The Impact Award supports research projects that have the strong potential to make a major impact on scientific and clinical prostate cancer issues, and ultimately make major advances toward eliminating death from prostate cancer and enhancing the well-being of Service members, Veterans, and all men experiencing the impact of the disease. The critical components of this award mechanism are:

• Impact: Research supported by the Impact Award will have the potential for a major, nearterm impact in addressing one or more of the FY18 PCRP Overarching Challenges. It is expected that the results of the proposed research will have the potential to transform the clinical management of prostate cancer within 5 years after the end of the award. It is the responsibility of the Principal Investigator (PI) to clearly and explicitly describe the potential impact of the proposed study on the clinical management of prostate cancer and to convey its level of significance. Applications must include a detailed transition plan that articulates the pathway to moving the project’s findings to the next phase of development after successful completion of the award, and how the PI will continue advancing the research towards making a clinical impact, even if clinical impact is not an immediate outcome.

• Research Scope: Proposed projects may include basic, translational, or clinical research, including clinical trials, but must demonstrate clinical relevance. Investigators from a wide spectrum of disciplines, including but not limited to, engineering, bioinformatics, population science, and psycho-oncology, are encouraged to apply, and multidisciplinary projects are encouraged. Only small-scale (i.e., up to and including Phase II or equivalent) clinical trials are allowed. Investigators proposing a clinical trial are highly encouraged to consider leveraging the PCRP-funded Prostate Cancer Clinical Trials Consortium (PCCTC) (http://pcctc.org/) to facilitate the rapid initiation and completion of the trial. Projects that incorporate population science-based approaches are particularly encouraged. Applications must include preliminary data to support feasibility of the study. Any unpublished, preliminary data provided should originate from the laboratory of the PI or a member(s) of the research team.

Deadlines:
• Pre-Application Submission Deadline: July 19, 2018
• Application Submission Deadline: October 18, 2018

Agency Website

Areas of Interest

The mission of the FY18 PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service members, Veterans, and all men experiencing the impact of the disease. Within this context, the PCRP is interested in supporting research that addresses specific gaps in prostate cancer research and clinical care. Therefore, applications are required to address one or more of the following FY18 PCRP Overarching Challenges:

• Develop treatments that improve outcomes for men with lethal prostate cancer

• Reduce lethal prostate cancer in African Americans, Veterans, and other high-risk populations

• Define the biology of lethal prostate cancer to reduce death 

• Improve the quality of life for survivors of prostate cancer

Eligibility Requirements

Independent investigators at or above the level of Assistant Professor (or equivalent).

Amount

$750,000

Amount Description

The anticipated direct costs budgeted for the entire period of performance for an FY18 PCRP Impact Award will not exceed $750,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information. 

Funding Type

Grant

Eligibility

Faculty
Junior Faculty

Category

Medical
Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

July 19, 2018